Mutual of America Capital Management LLC Decreases Holdings in DaVita Inc. (NYSE:DVA)

Mutual of America Capital Management LLC reduced its position in DaVita Inc. (NYSE:DVA) by 12.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,696 shares of the company’s stock after selling 844 shares during the period. Mutual of America Capital Management LLC’s holdings in DaVita were worth $934,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of DVA. Empowered Funds LLC increased its position in DaVita by 25.6% during the third quarter. Empowered Funds LLC now owns 5,824 shares of the company’s stock worth $955,000 after buying an additional 1,187 shares in the last quarter. Huntington National Bank increased its position in DaVita by 39.1% during the 3rd quarter. Huntington National Bank now owns 768 shares of the company’s stock worth $126,000 after purchasing an additional 216 shares in the last quarter. KBC Group NV increased its position in DaVita by 27.3% during the 3rd quarter. KBC Group NV now owns 313,519 shares of the company’s stock worth $51,395,000 after purchasing an additional 67,250 shares in the last quarter. Chase Investment Counsel Corp raised its stake in DaVita by 56.3% in the 3rd quarter. Chase Investment Counsel Corp now owns 33,084 shares of the company’s stock valued at $5,423,000 after purchasing an additional 11,912 shares during the last quarter. Finally, Verus Capital Partners LLC purchased a new position in DaVita in the 3rd quarter valued at about $213,000. 90.12% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DVA has been the topic of several recent analyst reports. Bank of America upped their price objective on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. Barclays raised their price objective on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Truist Financial upped their target price on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Finally, UBS Group raised their price target on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $161.80.

Insider Transactions at DaVita

In other DaVita news, CEO Javier Rodriguez sold 9,881 shares of DaVita stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $162.85, for a total value of $1,609,120.85. Following the completion of the sale, the chief executive officer now directly owns 887,835 shares in the company, valued at $144,583,929.75. The trade was a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.00% of the stock is owned by insiders.

DaVita Stock Up 0.6 %

Shares of DaVita stock opened at $167.98 on Wednesday. The business has a 50-day moving average price of $158.34 and a 200 day moving average price of $148.65. DaVita Inc. has a fifty-two week low of $98.26 and a fifty-two week high of $169.12. The firm has a market cap of $13.77 billion, a P/E ratio of 18.12, a P/E/G ratio of 0.93 and a beta of 0.89. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The firm had revenue of $3.26 billion during the quarter, compared to analyst estimates of $3.25 billion. During the same quarter in the previous year, the business posted $2.85 EPS. DaVita’s revenue for the quarter was up 4.6% compared to the same quarter last year. On average, sell-side analysts forecast that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.